Compare EFOI & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOI | SNSE |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 12.2M |
| IPO Year | 2004 | 2021 |
| Metric | EFOI | SNSE |
|---|---|---|
| Price | $2.05 | $30.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 10.9K | ★ 580.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $0.25 |
| 52 Week High | $3.56 | $36.76 |
| Indicator | EFOI | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 67.90 |
| Support Level | $1.79 | $7.94 |
| Resistance Level | $2.15 | $36.76 |
| Average True Range (ATR) | 0.09 | 4.36 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 57.84 | 75.01 |
Energy Focus Inc engages in the design, development, manufacturing, marketing, and sale of energy-efficient lighting systems and controls. The company serves the military maritime market and general commercial markets. Its product offerings include Military maritime LED lighting products such as military intelligible, globe lights, berth lights, and military fixtures and Commercial products such as LED fixtures and panels, LED down-lights, LED dock lights, and LED retrofit kits. Geographically, it operates in the United States and other countries. Its products include commercial products and MMM products. The company generates a majority of its sales from Military maritime products in the United States.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).